Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.

The Company Vision: To serve the needs of our patients and stakeholders to the best of our combined

The Company Mission: To bring life changing innovative medicines to patients in need and to add value for
all stakeholders through actively exercising our beliefs of honesty, integrity and collaboration.

The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results.  ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Latest News

Long COVID-19 strategic collaboration with US Experts

Positive PIP Decision from UK MHRA & ratification of PDCO opinion by EMA

ATL1102 Toxicology Protocol submitted to US FDA

Entitlement Offer Closing Date Extended

Positive Opinion received on ATL1102 Paediatric Investigation Plan & Successful capital raising to support Phase IIb/III EU clinical trial

Antisense Therapeutics appoints new Non-Executive Director

Positive feedback received on Paediatric Investigation Plan

Statistically significant modulation in two DMD disease modifier proteins supports potential of ATL1102 in ambulant DMD and fibrotic conditions

New ATL1102 proteomics data to be presented in a Late Breaking News Abstract at the World Muscle Society 2021 Virtual Congress